Compare TY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TY | IMCR |
|---|---|---|
| Founded | 1929 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 1994 | 2016 |
| Metric | TY | IMCR |
|---|---|---|
| Price | $35.32 | $36.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $66.33 |
| AVG Volume (30 Days) | 27.0K | ★ 390.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | N/A | $8.21 |
| P/E Ratio | ★ $7.50 | $157.91 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $30.53 | $27.56 |
| 52 Week High | $36.55 | $40.71 |
| Indicator | TY | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 61.32 |
| Support Level | $34.19 | $35.46 |
| Resistance Level | $35.85 | $37.38 |
| Average True Range (ATR) | 0.57 | 1.15 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 23.55 | 83.19 |
Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.